Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite first-line therapy, most patients with advanced esophageal squamous cell carcinoma (ESCC) experience disease progression and may become eligible for second-line chemotherapy. Although commonly used, the role of salvage chemotherapy in patients with recurrent or metastatic ESCC has not yet been established. We analyzed 53 patients who had received second-line chemotherapy after the failure of cisplatin-based combination chemotherapy with or without radiotherapy as first-line therapy in ESCC between March 2000 and June 2008. Median progression-free survival (PFS) and overall survival (OS) for second-line chemotherapy were 2.4 and 5.2 months, respectively, with an overall response rate of 18.9%. In multivariate analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2 or more and PFS under first-line therapy <4 months were independent prognostic factors for decreased OS. OS was estimated based on the number of adverse prognostic factors: 0 = good; 1 = intermediate, and 2 = poor. The median OS for the good, intermediate, and poor prognostic groups were 11.2, 4.5 and 4.3 months, respectively (p < 0.001). The good prognostic group showed better OS than the intermediate or poor groups (p < 0.001). Second-line chemotherapy may be beneficial for OS in ESCC patients with ECOG PS 0-1 and PFS under first-line therapy ≥4 months.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalOncology
Volume79
Issue number5-6
DOIs
Publication statusPublished - 2011 Apr 1

Fingerprint

Patient Selection
Squamous Cell Carcinoma
Drug Therapy
Survival
Disease-Free Survival
Therapeutics
Combination Drug Therapy
Cisplatin
Disease Progression
Radiotherapy
Multivariate Analysis
Esophageal Squamous Cell Carcinoma

Keywords

  • Chemotherapy, second line
  • Esophageal squamous cell carcinoma
  • Prognostic model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{47f4bbe7389a484395feb529228ed696,
title = "Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy",
abstract = "Despite first-line therapy, most patients with advanced esophageal squamous cell carcinoma (ESCC) experience disease progression and may become eligible for second-line chemotherapy. Although commonly used, the role of salvage chemotherapy in patients with recurrent or metastatic ESCC has not yet been established. We analyzed 53 patients who had received second-line chemotherapy after the failure of cisplatin-based combination chemotherapy with or without radiotherapy as first-line therapy in ESCC between March 2000 and June 2008. Median progression-free survival (PFS) and overall survival (OS) for second-line chemotherapy were 2.4 and 5.2 months, respectively, with an overall response rate of 18.9{\%}. In multivariate analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2 or more and PFS under first-line therapy <4 months were independent prognostic factors for decreased OS. OS was estimated based on the number of adverse prognostic factors: 0 = good; 1 = intermediate, and 2 = poor. The median OS for the good, intermediate, and poor prognostic groups were 11.2, 4.5 and 4.3 months, respectively (p < 0.001). The good prognostic group showed better OS than the intermediate or poor groups (p < 0.001). Second-line chemotherapy may be beneficial for OS in ESCC patients with ECOG PS 0-1 and PFS under first-line therapy ≥4 months.",
keywords = "Chemotherapy, second line, Esophageal squamous cell carcinoma, Prognostic model",
author = "Kim, {Seung Tae} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Shin, {Sang Won} and Kim, {Jun Suk} and Kim, {Yeul Hong}",
year = "2011",
month = "4",
day = "1",
doi = "10.1159/000322498",
language = "English",
volume = "79",
pages = "363--369",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5-6",

}

TY - JOUR

T1 - Selection of a patient subgroup with advanced esophageal squamous carcinoma who could benefit from second-line chemotherapy

AU - Kim, Seung Tae

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Shin, Sang Won

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Despite first-line therapy, most patients with advanced esophageal squamous cell carcinoma (ESCC) experience disease progression and may become eligible for second-line chemotherapy. Although commonly used, the role of salvage chemotherapy in patients with recurrent or metastatic ESCC has not yet been established. We analyzed 53 patients who had received second-line chemotherapy after the failure of cisplatin-based combination chemotherapy with or without radiotherapy as first-line therapy in ESCC between March 2000 and June 2008. Median progression-free survival (PFS) and overall survival (OS) for second-line chemotherapy were 2.4 and 5.2 months, respectively, with an overall response rate of 18.9%. In multivariate analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2 or more and PFS under first-line therapy <4 months were independent prognostic factors for decreased OS. OS was estimated based on the number of adverse prognostic factors: 0 = good; 1 = intermediate, and 2 = poor. The median OS for the good, intermediate, and poor prognostic groups were 11.2, 4.5 and 4.3 months, respectively (p < 0.001). The good prognostic group showed better OS than the intermediate or poor groups (p < 0.001). Second-line chemotherapy may be beneficial for OS in ESCC patients with ECOG PS 0-1 and PFS under first-line therapy ≥4 months.

AB - Despite first-line therapy, most patients with advanced esophageal squamous cell carcinoma (ESCC) experience disease progression and may become eligible for second-line chemotherapy. Although commonly used, the role of salvage chemotherapy in patients with recurrent or metastatic ESCC has not yet been established. We analyzed 53 patients who had received second-line chemotherapy after the failure of cisplatin-based combination chemotherapy with or without radiotherapy as first-line therapy in ESCC between March 2000 and June 2008. Median progression-free survival (PFS) and overall survival (OS) for second-line chemotherapy were 2.4 and 5.2 months, respectively, with an overall response rate of 18.9%. In multivariate analysis, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 2 or more and PFS under first-line therapy <4 months were independent prognostic factors for decreased OS. OS was estimated based on the number of adverse prognostic factors: 0 = good; 1 = intermediate, and 2 = poor. The median OS for the good, intermediate, and poor prognostic groups were 11.2, 4.5 and 4.3 months, respectively (p < 0.001). The good prognostic group showed better OS than the intermediate or poor groups (p < 0.001). Second-line chemotherapy may be beneficial for OS in ESCC patients with ECOG PS 0-1 and PFS under first-line therapy ≥4 months.

KW - Chemotherapy, second line

KW - Esophageal squamous cell carcinoma

KW - Prognostic model

UR - http://www.scopus.com/inward/record.url?scp=79952840480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952840480&partnerID=8YFLogxK

U2 - 10.1159/000322498

DO - 10.1159/000322498

M3 - Article

VL - 79

SP - 363

EP - 369

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5-6

ER -